Clinical Trial Update: TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating TGR-1202 in combination with ibrutinib for relapsed or refractory diffuse large B-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• TGR-1202 (umbralisib)

Snippet

Sponsor: University of Nebraska | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-02-26